Sonova Holding AG (CH:SOON)
:SOON
Top Page
Sonova Holding AG
(SOON)
Select Model
Select Model
Rating:68Neutral
Price Target:
CHF192.00
▼(-13.36% Downside)
Action:ReiteratedDate:11/17/25
Sonova Holding AG's overall stock score reflects strong financial performance and positive earnings call sentiment. However, bearish technical indicators and moderate valuation weigh down the score. The company's ability to maintain growth in key segments and manage challenges in others will be crucial for future performance.
Positive Factors
Profitability & Margins
Sustained high gross and operating margins alongside mid-single-digit revenue growth indicate durable pricing power and cost control in a specialized device market. Healthy margins provide long-term capacity to fund R&D, channel support, and retail operations while cushioning cyclical demand swings.
Negative Factors
Cochlear Implants Exposure
A segment-level sales decline tied to China points to geographic concentration and market-specific risks that can persist. Implant demand and regulatory/competitive dynamics in China could constrain long-term growth of this higher-value business if not addressed by local strategy adjustments.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability & Margins
Sustained high gross and operating margins alongside mid-single-digit revenue growth indicate durable pricing power and cost control in a specialized device market. Healthy margins provide long-term capacity to fund R&D, channel support, and retail operations while cushioning cyclical demand swings.
Read all positive factors
Sonova Holding AG (SOON) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF10.51B
Dividend Yield2.14%
Average Volume (3M)194.70K
Price to Earnings (P/E)17.1
Beta (1Y)0.77
Revenue Growth3.79%
EPS Growth-7.84%
CountryCH
Employees18,335
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)3.56
Shares Outstanding59,626,810
10 Day Avg. Volume113,155
30 Day Avg. Volume194,698
Financial Highlights & Ratios
PEG Ratio-2.82
Price to Book (P/B)5.74
Price to Sales (P/S)3.95
P/FCF Ratio23.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF205.33Price Target Upside-7.34% Downside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)10.64
Revenue Forecast (FY)CHF3.88B
Sonova Holding AG Business Overview & Revenue Model
Company Description
Sonova Holding AG designs, develops, manufactures, and distributes hearing care solutions for adults and children. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The company offers wireless communication prod...
How the Company Makes Money
Sonova primarily makes money by selling hearing-care products and services through a combination of wholesale distribution and owned retail. A core revenue stream is the sale of hearing instruments (hearing aids) and associated ecosystem products—...
Sonova Holding AG Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q2-2026)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Neutral
The earnings call conveyed optimism with strong growth in key segments, successful product launches, and maintained financial outlook. However, challenges in specific segments like Cochlear Implants and Consumer Hearing, along with the negative impact of the Swiss franc, tempered the overall positive narrative.Positive Updates
Strong Sales Growth in Key Segments
Hearing Instruments and Audiological Care saw a combined sales growth of 7% in local currencies, which is around twice the estimated market growth, resulting in significant market share gains.
Negative Updates
Challenges in Cochlear Implants and Consumer Hearing
Cochlear Implants faced a 5% decline in sales due to headwinds in China, while the Consumer Hearing business saw a 12% sales decline due to weak consumer demand and lack of new product launches.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Sales Growth in Key Segments
Hearing Instruments and Audiological Care saw a combined sales growth of 7% in local currencies, which is around twice the estimated market growth, resulting in significant market share gains.
Read all positive updates
Company Guidance
During the Sonova Half Year Results 2025-2026 Conference Call, the company provided guidance for the remainder of the fiscal year. Sonova confirmed its outlook for the full year, targeting 5% to 9% growth in sales and 14% to 18% growth in normalized EBITA, both measured at constant exchange rates. The company reported first-half sales of CHF 1.8 billion, reflecting a 4.9% increase in local currencies, and a normalized EBITA of CHF 316 million, up 16% in local currencies, with a margin expansion of 180 basis points. Sonova experienced strong performance in its Hearing Instruments and Audiological Care businesses, with a combined sales growth of 7%. Despite challenges in its Consumer Hearing and Cochlear Implants segments, the company remains confident in maintaining positive momentum, driven by recent product launches such as Virto R, Infinio Ultra, and Infinio Ultra Sphere, which are expected to contribute to growth in the second half.Sonova Holding AG Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.85B | 3.87B | 3.63B | 3.74B | 3.36B | 2.60B |
| Gross Profit | 2.71B | 2.78B | 2.61B | 2.59B | 2.46B | 1.87B |
| EBITDA | 892.00M | 927.00M | 917.90M | 974.50M | 893.10M | 818.60M |
| Net Income | 520.50M | 540.50M | 601.00M | 647.50M | 649.00M | 581.00M |
Balance Sheet | ||||||
| Total Assets | 5.51B | 5.92B | 5.79B | 5.55B | 5.59B | 5.93B |
| Cash, Cash Equivalents and Short-Term Investments | 511.00M | 687.10M | 513.80M | 414.80M | 612.00M | 1.77B |
| Total Debt | 1.85B | 1.76B | 1.79B | 1.81B | 1.48B | 1.83B |
| Total Liabilities | 3.06B | 3.24B | 3.30B | 3.32B | 3.16B | 3.15B |
| Stockholders Equity | 2.43B | 2.66B | 2.47B | 2.21B | 2.41B | 2.75B |
Cash Flow | ||||||
| Free Cash Flow | 713.20M | 656.10M | 624.70M | 609.10M | 815.90M | 665.50M |
| Operating Cash Flow | 816.60M | 793.70M | 753.30M | 763.40M | 922.50M | 754.70M |
| Investing Cash Flow | -259.30M | -212.70M | -234.00M | -429.50M | -707.00M | -123.60M |
| Financing Cash Flow | -312.50M | -401.80M | -415.30M | -523.50M | -1.37B | 687.60M |
Sonova Holding AG Technical Analysis
Neutral
221.60
Price Trends
192.08
Negative
199.68
Negative
213.90
Negative
Market Momentum
-3.76
Negative
48.52
Neutral
78.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SOON, the sentiment is Neutral. The current price of 221.6 is above the 20-day moving average (MA) of 180.00, above the 50-day MA of 192.08, and above the 200-day MA of 213.90, indicating a neutral trend. The MACD of -3.76 indicates Negative momentum. The RSI at 48.52 is Neutral, neither overbought nor oversold. The STOCH value of 78.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:SOON.
Sonova Holding AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | CHF3.91B | 7.66 | 27.15% | 0.67% | 27.63% | 160.67% | |
68 Neutral | CHF10.51B | 17.11 | ― | 2.14% | 3.79% | -7.84% | |
66 Neutral | CHF13.44B | 41.72 | ― | 1.02% | 4.49% | 45.08% | |
64 Neutral | CHF3.07B | 34.95 | 23.76% | 0.45% | 16.59% | 65.76% | |
55 Neutral | CHF1.73B | -3.17 | 4.57% | 2.31% | -9.34% | -37.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | CHF1.11B | 131.13 | ― | ― | 7.29% | -112.70% |
* Healthcare Sector Average
CH:SOON
Sonova Holding AG
182.70
-48.87
-21.10%
CH:STMN
Straumann Holding AG
84.30
-12.78
-13.16%
CH:MOVE
Medacta Group SA
153.40
35.19
29.76%
CH:TECN
Tecan Group AG
134.90
-10.30
-7.09%
CH:YPSN
Ypsomed Holding AG
287.00
-33.80
-10.54%
CH:MED
Medartis Holding AG
81.60
10.90
15.42%
Sonova Holding AG Corporate Events
Sonova sets up APAC hub and innovation center in Singapore to drive regional growth
Mar 31, 2026
Sonova Holding AG, the Swiss-based global provider of hearing care solutions, is deepening its presence in Asia Pacific through a strategic partnership with the Singapore Economic Development Board. The company will establish an Innovation Center ...
Sonova Sharpens Hearing-Care Focus, Sets CHF 6 Billion Sales Target by 2030/31
Mar 23, 2026
Sonova has unveiled a sharpened strategy to reinforce its market leadership in hearing care by fully focusing on hearing aids and cochlear implants and exiting its Consumer Hearing business under the Sennheiser brand. Management targets revenue of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.